{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53159"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53159","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Evaluation of NarcoTrace immunoassay and recovery of DNA","abstract":"Driving under the influence of drugs (DUID) is a worldwide problem that is frequently encountered in routine vehicular stops by law enforcement or is the cause of impaired driving. Impaired driving can result in preventable accidents or in more serious instances, death. Drug identification in DUID cases provides valuable evidence in the legal process of charging drug impaired drivers. Additionally, making associations between the drug evidence and the suspect via deoxyribonucleic acid (DNA) identification can help strengthen its evidentiary value. Collaborations between law enforcement and forensic toxicological testing can contribute to drug identification paired with DNA associations and assist with successful prosecution of DUID cases. This study evaluated a qualitative toxicology test utilizing NarcoTrace™, a competitive lateral flow immunoassay (LFIA), for the detection of cocaine (COC), benzoylecgonine (BE), fentanyl (FEN), delta-9-tetrahydrocannabinol (THC), d-Methamphetamine (MET), d-Amphetamine (AMP), morphine (OPI), and 3,4-Methylenedioxymethamphetamine (MDMA) in oral fluid samples. Toxicology testing was then followed with DNA quantification of the portion of the NarcoTrace™ device containing the oral fluid. Toxicological evaluation included assessing the NarcoTrace™ effectiveness at detecting high dose and polydrug oral fluid samples at the manufacturer cutoff levels. Only 2 of the 8 drugs evaluated, benzoylecgonine and d-Amphetamine, achieved positive results. All samples exhibited sufficient quantities for DNA amplification and analysis which provided a successful DNA linkage.","abstract_html":"Driving under the influence of drugs (DUID) is a worldwide problem that is frequently encountered in routine vehicular stops by law enforcement or is the cause of impaired driving. Impaired driving can result in preventable accidents or in more serious instances, death. Drug identification in DUID cases provides valuable evidence in the legal process of charging drug impaired drivers. Additionally, making associations between the drug evidence and the suspect via deoxyribonucleic acid (DNA) identification can help strengthen its evidentiary value. Collaborations between law enforcement and forensic toxicological testing can contribute to drug identification paired with DNA associations and assist with successful prosecution of DUID cases. This study evaluated a qualitative toxicology test utilizing NarcoTrace™, a competitive lateral flow immunoassay (LFIA), for the detection of cocaine (COC), benzoylecgonine (BE), fentanyl (FEN), delta-9-tetrahydrocannabinol (THC), d-Methamphetamine (MET), d-Amphetamine (AMP), morphine (OPI), and 3,4-Methylenedioxymethamphetamine (MDMA) in oral fluid samples. Toxicology testing was then followed with DNA quantification of the portion of the NarcoTrace™ device containing the oral fluid. Toxicological evaluation included assessing the NarcoTrace™ effectiveness at detecting high dose and polydrug oral fluid samples at the manufacturer cutoff levels. Only 2 of the 8 drugs evaluated, benzoylecgonine and d-Amphetamine, achieved positive results. All samples exhibited sufficient quantities for DNA amplification and analysis which provided a successful DNA linkage.","abstract_has_math":false,"creators":["Gutierrez, Javier"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Anatomy & Neurobiology","degree_department":null,"school":null,"contributors":[],"advisors":["Wareing, Celeste M."],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-11-18T20:27:03Z","subjects":["Toxicology","Biology"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/53159","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53159","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53159","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Wareing, Celeste M."]},{"key":"dc:creator","label":"Author","values":["Gutierrez, Javier"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-06-17T13:33:49Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2026-06-17T13:33:49Z"]},{"key":"dc:date.issued","label":"Date","values":["2025"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-06-16T22:03:17Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Anatomy & Neurobiology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Toxicology","Biology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53159"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2025"]},{"key":"dc:description.abstract","label":"Abstract","values":["Driving under the influence of drugs (DUID) is a worldwide problem that is frequently encountered in routine vehicular stops by law enforcement or is the cause of impaired driving. Impaired driving can result in preventable accidents or in more serious instances, death. Drug identification in DUID cases provides valuable evidence in the legal process of charging drug impaired drivers. Additionally, making associations between the drug evidence and the suspect via deoxyribonucleic acid (DNA) identification can help strengthen its evidentiary value. Collaborations between law enforcement and forensic toxicological testing can contribute to drug identification paired with DNA associations and assist with successful prosecution of DUID cases. This study evaluated a qualitative toxicology test utilizing NarcoTrace™, a competitive lateral flow immunoassay (LFIA), for the detection of cocaine (COC), benzoylecgonine (BE), fentanyl (FEN), delta-9-tetrahydrocannabinol (THC), d-Methamphetamine (MET), d-Amphetamine (AMP), morphine (OPI), and 3,4-Methylenedioxymethamphetamine (MDMA) in oral fluid samples. Toxicology testing was then followed with DNA quantification of the portion of the NarcoTrace™ device containing the oral fluid. Toxicological evaluation included assessing the NarcoTrace™ effectiveness at detecting high dose and polydrug oral fluid samples at the manufacturer cutoff levels. Only 2 of the 8 drugs evaluated, benzoylecgonine and d-Amphetamine, achieved positive results. All samples exhibited sufficient quantities for DNA amplification and analysis which provided a successful DNA linkage."]},{"key":"dc:title","label":"Title","values":["Evaluation of NarcoTrace immunoassay and recovery of DNA"]}]}],"canonical_facts":{"dc:contributor.advisor":["Wareing, Celeste M."],"dc:creator":["Gutierrez, Javier"],"dc:date.accessioned":["2026-06-17T13:33:49Z"],"dc:date.available":["2026-06-17T13:33:49Z"],"dc:date.issued":["2025"],"dc:date.updated":["2026-06-16T22:03:17Z"],"dc:description":["2025"],"dc:description.abstract":["Driving under the influence of drugs (DUID) is a worldwide problem that is frequently encountered in routine vehicular stops by law enforcement or is the cause of impaired driving. Impaired driving can result in preventable accidents or in more serious instances, death. Drug identification in DUID cases provides valuable evidence in the legal process of charging drug impaired drivers. Additionally, making associations between the drug evidence and the suspect via deoxyribonucleic acid (DNA) identification can help strengthen its evidentiary value. Collaborations between law enforcement and forensic toxicological testing can contribute to drug identification paired with DNA associations and assist with successful prosecution of DUID cases. This study evaluated a qualitative toxicology test utilizing NarcoTrace™, a competitive lateral flow immunoassay (LFIA), for the detection of cocaine (COC), benzoylecgonine (BE), fentanyl (FEN), delta-9-tetrahydrocannabinol (THC), d-Methamphetamine (MET), d-Amphetamine (AMP), morphine (OPI), and 3,4-Methylenedioxymethamphetamine (MDMA) in oral fluid samples. Toxicology testing was then followed with DNA quantification of the portion of the NarcoTrace™ device containing the oral fluid. Toxicological evaluation included assessing the NarcoTrace™ effectiveness at detecting high dose and polydrug oral fluid samples at the manufacturer cutoff levels. Only 2 of the 8 drugs evaluated, benzoylecgonine and d-Amphetamine, achieved positive results. All samples exhibited sufficient quantities for DNA amplification and analysis which provided a successful DNA linkage."],"dc:identifier.uri":["https://hdl.handle.net/2144/53159"],"dc:language.iso":["en_US"],"dc:subject":["Toxicology","Biology"],"dc:title":["Evaluation of NarcoTrace immunoassay and recovery of DNA"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Anatomy & Neurobiology"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:27:03Z"}